Leishmaniasis (Kala-Azar) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Leishmaniasis (Kala-Azar) – Pipeline Review, H2 2016’, provides an overview of the Leishmaniasis (Kala-Azar) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Leishmaniasis (Kala-Azar), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Leishmaniasis (Kala-Azar) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Leishmaniasis (Kala-Azar)

The report reviews pipeline therapeutics for Leishmaniasis (Kala-Azar) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Leishmaniasis (Kala-Azar) therapeutics and enlists all their major and minor projects

The report assesses Leishmaniasis (Kala-Azar) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Leishmaniasis (Kala-Azar)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Leishmaniasis (Kala-Azar)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Leishmaniasis (Kala-Azar) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Advinus Therapeutics Ltd

BioLingus AG

iCo Therapeutics Inc.

Laboratorios LETI S.L.

ManRos Therapeutics

Matinas BioPharma Holdings, Inc.

Nanomerics Ltd

Novartis AG

Oblita Therapeutics BVBA

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Leishmaniasis (Kala-Azar) Overview 10

Therapeutics Development 11

Pipeline Products for Leishmaniasis (Kala-Azar) - Overview 11

Pipeline Products for Leishmaniasis (Kala-Azar) - Comparative Analysis 12

Leishmaniasis (Kala-Azar) - Therapeutics under Development by Companies 13

Leishmaniasis (Kala-Azar) - Therapeutics under Investigation by Universities/Institutes 15

Leishmaniasis (Kala-Azar) - Pipeline Products Glance 16

Late Stage Products 16

Clinical Stage Products 17

Early Stage Products 18

Unknown Stage Products 19

Leishmaniasis (Kala-Azar) - Products under Development by Companies 20

Leishmaniasis (Kala-Azar) - Products under Investigation by Universities/Institutes 21

Leishmaniasis (Kala-Azar) - Companies Involved in Therapeutics Development 22

Advinus Therapeutics Ltd 22

BioLingus AG 23

iCo Therapeutics Inc. 24

Laboratorios LETI S.L. 25

ManRos Therapeutics 26

Matinas BioPharma Holdings, Inc. 27

Nanomerics Ltd 28

Novartis AG 29

Oblita Therapeutics BVBA 30

Leishmaniasis (Kala-Azar) - Therapeutics Assessment 31

Assessment by Monotherapy Products 31

Assessment by Combination Products 32

Assessment by Target 33

Assessment by Mechanism of Action 35

Assessment by Route of Administration 37

Assessment by Molecule Type 39

Drug Profiles 41

(gentamicin sulfate + paromomycin sulfate) - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

18-MC - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

amphotericin B - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

amphotericin B - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

amphotericin B - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

amphotericin B - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

Amphotericin B sodium - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

candicidin - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

CDRI-99288 - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

D-121 - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

Drugs for Leishmaniasis and Trypanosomiasis - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

GNF-6702 - Drug Profile 57

Product Description 57

Mechanism Of Action 57

R&D Progress 57

hypoestoxide - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

interferon gamma - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

KVH-14 - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

leishmaniasis vaccine - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

leishmaniasis vaccine - Drug Profile 62

Product Description 62

Mechanism Of Action 62

R&D Progress 62

leishmaniasis vaccine - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

leishmaniasis vaccine - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

leishmaniasis vaccine 2 - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

NPC-1161B - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

P-MAPA - Drug Profile 67

Product Description 67

Mechanism Of Action 67

R&D Progress 67

Peptides for Infectious Diseases - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

S-010269 - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

SJL-01 - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

Small Molecule for Leishmaniasis - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

Small Molecule for Leishmaniasis - Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

Small Molecule for Visceral Leishmaniasis - Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

Small Molecule to Inhibit SOD for Chagas Disease and Leishmaniasis - Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

Small Molecules for Infectious Diseases - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

Small Molecules for Infectious Diseases - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

Small Molecules for Leishmaniasis - Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

Small Molecules for Leishmaniasis - Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

Small Molecules for Visceral Leishmaniasis - Drug Profile 80

Product Description 80

Mechanism Of Action 80

R&D Progress 80

Small Molecules for Visceral Leishmaniasis - Drug Profile 81

Product Description 81

Mechanism Of Action 81

R&D Progress 81

Small Molecules to Block LHR1 for Leishmaniasis - Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

Small Molecules to Inhibit HDAC for Oncology and Infectious Diseases - Drug Profile 83

Product Description 83

Mechanism Of Action 83

R&D Progress 83

Small Molecules to Inhibit Lanosterol 14 alpha-Demethylase for Chagas Disease and Leishmaniasis - Drug Profile 84

Product Description 84

Mechanism Of Action 84

R&D Progress 84

Small Molecules to Inhibit Leishmania Major Casein Kinase 1 Isoform 2 for Leishmaniasis - Drug Profile 85

Product Description 85

Mechanism Of Action 85

R&D Progress 85

Small Molecules to Inhibit Nucleoside Hydrolase for Leishmaniasis - Drug Profile 86

Product Description 86

Mechanism Of Action 86

R&D Progress 86

Synthetic Peptides for Infectious Disease - Drug Profile 87

Product Description 87

Mechanism Of Action 87

R&D Progress 87

Vaccine for Leishmaniasis - Drug Profile 88

Product Description 88

Mechanism Of Action 88

R&D Progress 88

visceral leishmaniasis vaccine - Drug Profile 89

Product Description 89

Mechanism Of Action 89

R&D Progress 89

Leishmaniasis (Kala-Azar) - Dormant Projects 90

Leishmaniasis (Kala-Azar) - Discontinued Products 92

Leishmaniasis (Kala-Azar) - Product Development Milestones 93

Featured News & Press Releases 93

Dec 15, 2015: U.S. Issues Patent on Corifungin 93

Oct 26, 2015: iCo Therapeutics Announces Manufacturing Update for Oral Amp B Program 93

Feb 13, 2015: Nanomerics Oral Amphotericin B Promises Better Treatment for Millions 93

Oct 06, 2014: Phase III Clinical Study in Ethiopia Launched to Test Two Treatments for HIV-Visceral Leishmaniasis Co-infected Patients 94

Feb 26, 2013: National Institutes of Health Supports Acea’s Research 95

Mar 06, 2012: £10 million boost for neglected tropical disease research at Dundee 95

Feb 22, 2012: IDRI Launches First Clinical Trial For New Vaccine To Treat Leishmaniasis 96

Oct 24, 2011: iCo Therapeutics Oral Amphotericin B Delivery System To Be Presented At AAPS 97

Jul 01, 2011: FDA issues orphan-drug designation to Corifungin 98

Sep 29, 2010: iCo Therapeutics Oral Amphotericin Program Receives FDA Orphan Drug Status 98

Feb 10, 2010: Dr. Jose Vazquez presents poster at ICAAC 99

Dec 14, 2005: Collaboration on the Development of Anti-Parasitic Drugs for Both Malaria and Leishmaniasis 99

Appendix 101

Methodology 101

Coverage 101

Secondary Research 101

Primary Research 101

Expert Panel Validation 101

Contact Us 101

Disclaimer 102

List of Tables

List of Tables

Number of Products under Development for Leishmaniasis (Kala-Azar), H2 2016 11

Number of Products under Development for Leishmaniasis (Kala-Azar) – Comparative Analysis, H2 2016 12

Number of Products under Development by Companies, H2 2016 14

Number of Products under Investigation by Universities/Institutes, H2 2016 15

Comparative Analysis by Late Stage Development, H2 2016 16

Comparative Analysis by Clinical Stage Development, H2 2016 17

Comparative Analysis by Early Stage Development, H2 2016 18

Comparative Analysis by Unknown Stage Development, H2 2016 19

Products under Development by Companies, H2 2016 20

Products under Investigation by Universities/Institutes, H2 2016 21

Leishmaniasis (Kala-Azar) – Pipeline by Advinus Therapeutics Ltd, H2 2016 22

Leishmaniasis (Kala-Azar) – Pipeline by BioLingus AG, H2 2016 23

Leishmaniasis (Kala-Azar) – Pipeline by iCo Therapeutics Inc., H2 2016 24

Leishmaniasis (Kala-Azar) – Pipeline by Laboratorios LETI S.L., H2 2016 25

Leishmaniasis (Kala-Azar) – Pipeline by ManRos Therapeutics, H2 2016 26

Leishmaniasis (Kala-Azar) – Pipeline by Matinas BioPharma Holdings, Inc. , H2 2016 27

Leishmaniasis (Kala-Azar) – Pipeline by Nanomerics Ltd, H2 2016 28

Leishmaniasis (Kala-Azar) – Pipeline by Novartis AG, H2 2016 29

Leishmaniasis (Kala-Azar) – Pipeline by Oblita Therapeutics BVBA, H2 2016 30

Assessment by Monotherapy Products, H2 2016 31

Assessment by Combination Products, H2 2016 32

Number of Products by Stage and Target, H2 2016 34

Number of Products by Stage and Mechanism of Action, H2 2016 36

Number of Products by Stage and Route of Administration, H2 2016 38

Number of Products by Stage and Molecule Type, H2 2016 40

Leishmaniasis (Kala-Azar) – Dormant Projects, H2 2016 90

Leishmaniasis (Kala-Azar) – Dormant Projects (Contd..1), H2 2016 91

Leishmaniasis (Kala-Azar) – Discontinued Products, H2 2016 92

List of Figures

List of Figures

Number of Products under Development for Leishmaniasis (Kala-Azar), H2 2016 11

Number of Products under Development for Leishmaniasis (Kala-Azar) – Comparative Analysis, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Number of Products under Investigation by Universities/Institutes, H2 2016 15

Comparative Analysis by Clinical Stage Development, H2 2016 17

Comparative Analysis by Early Stage Products, H2 2016 18

Assessment by Monotherapy Products, H2 2016 31

Number of Products by Top 10 Targets, H2 2016 33

Number of Products by Stage and Top 10 Targets, H2 2016 33

Number of Products by Top 10 Mechanism of Actions, H2 2016 35

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 35

Number of Products by Routes of Administration, H2 2016 37

Number of Products by Stage and Routes of Administration, H2 2016 37

Number of Products by Molecule Types, H2 2016 39

Number of Products by Stage and Molecule Types, H2 2016 39

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports